Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Sundy, J.S.; Ganson, N.J.; Kelly, S.J.; Scarlett, E.L.; Rehrig, C.D.; Huang, W.; Hershfield, M.S.
    Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout (2007), Arthritis Rheum., 56, 1021-1028.
    View publication on PubMed

Application

EC Number Application Comment Organism
1.7.3.3 medicine the enzyme might be useful in the treatment of patients with refractory gout, overview Sus scrofa

Protein Variants

EC Number Protein Variants Comment Organism
1.7.3.3 additional information the recombinantly expressed porcine enzyme, with a C-terminal sequence from baboon uricase, is applicated to patients with refractory gout, due to a mutation in the uricase gene, by intravenous injection in a PEG-bound form, pharmacokinetics and pharmacodynamics, safety, and efficacy of the treatment in a clinical trial, overview Sus scrofa

Organism

EC Number Organism UniProt Comment Textmining
1.7.3.3 Sus scrofa P16164
-
-

Synonyms

EC Number Synonyms Comment Organism
1.7.3.3 uricase
-
Sus scrofa